Dominik Höchli
Director/Board Member bij MOLECULAR PARTNERS AG
Profiel
Dominik Höchli is currently the Chief Executive Officer at Catapult Therapeutics BV and an Independent Director at Molecular Partners AG.
He previously worked as the Vice President & Head-Global Medical Affairs at AbbVie AG.
He holds a doctorate degree from the University of Bern.
Actieve functies van Dominik Höchli
| Bedrijven | Functie | Begin |
|---|---|---|
| MOLECULAR PARTNERS AG | Director/Board Member | 21-04-2021 |
Catapult Therapeutics BV
 Catapult Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Catapult Therapeutics BV operates as a biopharmaceutical company which develops cancer treatments. It is developing CAP-100, a humanized anti-CCR7 antibody. The company was founded in 2015 and is headquartered in Lelystad, the Netherlands. | Chief Executive Officer | 01-01-2021 |
Eerdere bekende functies van Dominik Höchli
| Bedrijven | Functie | Einde |
|---|---|---|
| AbbVie AG | Corporate Officer/Principal | - |
Opleiding van Dominik Höchli
| University of Bern | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| MOLECULAR PARTNERS AG | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
| AbbVie AG | |
Catapult Therapeutics BV
Catapult Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Catapult Therapeutics BV operates as a biopharmaceutical company which develops cancer treatments. It is developing CAP-100, a humanized anti-CCR7 antibody. The company was founded in 2015 and is headquartered in Lelystad, the Netherlands. | Commercial Services |
